Q32 Bio (QTTB) Research & Development (2017 - 2026)

Q32 Bio's Research & Development history runs 10 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• On a quarterly basis, Research & Development fell 54.83% year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was $15.2 million, a 66.43% decrease from a year earlier, with the FY2025 full-year figure at $19.2 million, down 60.21% from the prior year.
• Research & Development slipped to $3.2 million in Q1 2026 per QTTB's latest filing, from $3.3 million in the prior quarter.
• Across five years, Research & Development topped out at $27.1 million in Q4 2022 and bottomed at $3.2 million in Q1 2026.
• The 5-year median for Research & Development is $8.3 million (2023), against an average of $11.8 million.
• Across the five-year window, Research & Development soared 92.23% in 2024 and slumped 75.22% in 2025, its largest moves.
• Year by year, Research & Development stood at $27.1 million in 2022, then tumbled by 69.28% to $8.3 million in 2023, then climbed by 26.45% to $10.5 million in 2024, then sank by 68.56% to $3.3 million in 2025, then slipped by 2.93% to $3.2 million in 2026.
• Per Business Quant, the three latest QTTB Research & Development figures stand at $3.2 million (Q1 2026), $3.3 million (Q4 2025), and $3.6 million (Q3 2025).